Cited by 193Pharmacology and Obesity TreatmentObesity, Physical Activity, DietBariatric Surgery and Outcomes

Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children

Open access
Yanovski, Jack A., Krakoff, Jonathan, Salaita, Christine G., McDuffie, Jennifer R., Kozlosky, Merel, Sebring, Nancy G., Reynolds, James C., Brady, Sheila M. +1 more·2011·Diabetes

Abstract

OBJECTIVE: Metformin can decrease adiposity and ameliorate obesity-related comorbid conditions, including abnormalities in glucose homeostasis in adolescents, but there are few data evaluating the efficacy of metformin among younger children. Our objective was to determine whether metformin treatment causes weight loss and improves obesity-related comorbidities in obese children, who are insulin-resistant. RESEARCH DESIGN AND METHODS: This study was a randomized double-blind placebo-controlled trial consisting of 100 severely obese (mean BMI 34.6 ± 6.6 kg/m(2)) insulin-resistant children aged 6-12 years, randomized to 1,000 mg metformin (n = 53) or placebo (n = 47) twice daily for 6 months, followed by open-label metformin treatment for 6 months. All children and their parents participated in a monthly dietitian-administered weight-reduction program. RESULTS: Eighty-five percent completed the 6-month randomized phase. Children prescribed metformin had significantly greater decreases in BMI (difference -1.09 kg/m(2), CI -1.87 to -0.31, P = 0.006), body weight (difference -3.38 kg, CI -5.2 to -1.57, P < 0.001), BMI Z score (difference between metformin and placebo groups -0.07, CI -0.12 to -0.01, P = 0.02), and fat mass (difference -1.40 kg, CI -2.74 to -0.06, P = 0.04). Fasting plasma glucose (P = 0.007) and homeostasis model assessment (HOMA) insulin resistance index (P = 0.006) also improved more in metformin-treated children than in placebo-treated children. Gastrointestinal symptoms were significantly more prevalent in metformin-treated children, which limited maximal tolerated dosage in 17%. During the 6-month open-label phase, children treated previously with placebo decreased their BMI Z score; those treated continuously with metformin did not significantly change BMI Z score further. CONCLUSIONS: Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-1185

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yanovski, J. A., Krakoff, J., Salaita, C. G., McDuffie, J. R., Kozlosky, M., Sebring, N. G., Reynolds, J. C., Brady, S. M., & Calis, K. A.
Affiliations
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
  • National Institutes of Health (US)
Corresponding author
Yanovski, Jack A.
Venue
Diabetes
Published
2011-01-21
Volume
60
Issue
2
Pages
477-485
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2110798021
Cited by
193
References
53
Citations by year
2026: 8 · 2025: 7 · 2024: 8 · 2023: 13 · 2022: 4 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 17 · 2017: 18 · 2016: 24 · 2015: 8 · 2014: 15 · 2013: 18 · 2012: 15
FWCI
12.65
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD000641)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
metformin, childhood obesity, insulin resistance, weight loss, body composition, fat mass, glucose homeostasis, fasting blood glucose, HOMA-IR, slimming program, gastrointestinal adverse effects
MeSH terms
Body Composition, Body Weight, Child, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Obesity, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review